Trusted Supply of Critical & Orphan Medicines, Worldwide!

Drug: Sotorasib
Brand: Sotorasib 120mg
Manufacturer /
TM Owner
Amgen
Origin: USA

Sotorasib 120mg Tablet

Sotorasib is a prescription lung cancer medicine based on Sotorasib. It acts on the underlying disease process to relieve symptoms and improve clinical outcomes. It is used in the treatment of lung cancer. It is supplied as a tablet (120mg). It offers patients a well-established, evidence-based option prescribed and monitored by specialists.
Strength: 120mg
Pack Size: 240s
Storage: 20°C to 25°C
Form: Tablet

+91 900 500 9556

Global Shipping : Reliable Global Distribution Network

Express Delivery : Priority Shipping for Every Order

Secure Payments : Trusted Payment Protection System

Disclaimer
All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the 'Manufacturer/ TM Owner' section in compliance with statutory requirements. Read More

Secure Handling

24/7 Worldwide Support

Global Access

Worldwide Access to Health

Cold-Chain Expert

Excellence in Cold-Chain

Trusted Supply

Certified Medical Supply

Indications & Clinical Uses

  • Sotorasib, marketed as Lumakras in the United States (Lumykras in the European Union), is a targeted KRAS G12C inhibitor tablet made by Amgen.
  • It is approved for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have already had at least one other systemic treatment, under the US accelerated-approval pathway, and, in combination with the antibody panitumumab, for KRAS G12C-mutated metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
  • Treatment requires a confirmed KRAS G12C mutation on an FDA-approved test before starting.
  • It is an oral, self-administered tablet taken at home rather than a hospital-given infusion, though regular clinic visits for blood tests and monitoring are required throughout treatment.
  • It is not approved for children.

Side Effects

  • When sotorasib is used alone for lung cancer, the most common side effects (each affecting one in five patients or more) are diarrhea, musculoskeletal pain, nausea, fatigue, cough and raised liver enzymes; when combined with panitumumab for colorectal cancer, rash, dry skin, diarrhea and mouth sores are also common.
  • Sotorasib carries no boxed warning, but liver injury (hepatotoxicity) affects around a quarter of patients on monotherapy, so blood tests to check liver function are done every three weeks for the first three months, then monthly.
  • A less common but serious effect is interstitial lung disease or pneumonitis, which can be fatal; tell your healthcare provider immediately about new or worsening cough, shortness of breath or fever, and about any yellowing of the skin or eyes.

Precautions & Warnings

  • Liver function tests must be checked before starting sotorasib, every three weeks for the first three months, then monthly or as clinically indicated, since hepatotoxicity is common; treatment may be interrupted, reduced or stopped depending on severity.
  • Sotorasib must be stopped immediately if interstitial lung disease or pneumonitis is suspected and permanently discontinued if confirmed.
  • Take tablets whole, without crushing, chewing or splitting, at the same time each day, with or without food.
  • Effective contraception is recommended during treatment and for a period after the last dose, and breastfeeding is not recommended during treatment or for one week afterward.
  • Safety and effectiveness have not been established in children.
  • Tell your healthcare provider about all other medicines, since dose adjustments or timing changes are often needed.

Avoid Interactions

  • Do not take proton pump inhibitors or H2-receptor blockers with sotorasib, since reducing stomach acid lowers its absorption; if a locally acting antacid is unavoidable, take it at least four hours before or ten hours after sotorasib.
  • Avoid strong or moderate CYP3A4 inducers, which can reduce sotorasib's effect.
  • Sotorasib itself can lower the levels and effectiveness of many CYP3A4-metabolised medicines, including some hormonal contraceptives, so alternative contraception may be needed, and it can raise levels of sensitive P-glycoprotein substrate drugs such as digoxin, increasing the risk of side effects.
  • Tell your healthcare provider and pharmacist about every prescription and over-the-counter medicine, herbal product and supplement you take before and during treatment.

References

Frequently Asked Questions

Sotorasib, sold as Lumakras, treats KRAS G12C-mutated non-small cell lung cancer in adults who have had prior treatment, and, combined with panitumumab, KRAS G12C-mutated colorectal cancer after earlier chemotherapy. A specific genetic test must confirm the KRAS G12C mutation before starting. It is taken as a once-daily tablet.

Simple Working Process

We have simplified the online drug ordering process into 4 easy steps to ensure
a safe, secure, and hassle-free experience for our customers.


Order Online

Place your order online and upload prescription in minutes with ease.



Order Confirmation

We verify your prescription and confirm your order quickly and securely.



Prescription Review

Reviewed by licensed pharmacists. Carefully processed and validated.

R

Receive Medicines

Approved order delivered fast, easy, and right to your doorstep or nearby Airport.



Global Standards. Trusted Care.

Trusted & Reliable – Your Partner in Global Distribution.

We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.